查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1847866

按產品類型、應用和最終用戶分類的切片檢查設備市場 - 全球預測 2025-2032

Biopsy Devices Market by Product Type, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，切片檢查設備市場規模將達到 244.5 億美元，複合年成長率為 11.19%。

主要市場統計數據
基準年 2024 104.6億美元
預計年份：2025年 116.1億美元
預測年份：2032年 244.5億美元
複合年成長率 (%) 11.19%

這份簡明扼要的切片檢查設備概覽涵蓋了臨床促進因素、技術進步、監管環境以及領導者的採購重點。

切片檢查設備在腫瘤科、腎臟科、肝病科和肺科的診斷流程中至關重要，其發展演變直接影響臨床工作流程、設備應用和採購重點。目前的主要促進因素包括技術創新融合、流程標準化以及對微創技術的日益重視，這些技術優先考慮患者舒適度和診斷效果。同時，監管機構的監管和支付方的政策也影響著設備的設計、臨床證據的產生和價值論證，這些因素共同決定整個醫療保健領域的設備普及率。

隨著分子診斷和新一代定序技術逐漸成為臨床決策的常規組成部分，臨床醫生正在尋求能夠縮短手術時間並提高樣本品質的設備。因此，製造商正致力於研發精準的引導系統、自動化採樣機制以及能夠與數位病理和資料管理工具整合的平台。同時，醫療機構也在權衡資本投資與吞吐量需求，這使得生命週期成本、培訓要求以及與現有影像和內視鏡設備的互通性變得愈發重要。

展望未來，相關人員必須兼顧臨床需求與經濟現實。採購團隊和臨床領導者越來越要求提供受控實驗室測試之外的實際療效和營運效益證據。因此，設備開發人員和策略團隊應優先考慮可靠的臨床檢驗、以使用者為中心的設計以及能夠引起臨床醫生和醫院管理者共鳴的清晰價值主張。總而言之，這些因素共同構成了一個複雜但可行的切片檢查技術創新和應用環境。

對正在重塑醫療保健環境中切片檢查設備使用和檢驗的技術整合、自動化和不斷發展的臨床工作流程進行了詳細的綜合分析。

切片檢查設備領域正經歷著變革性的轉變，這主要得益於影像、自動化和數據主導診斷技術的整合發展。這些趨勢正在重塑切片檢查的操作方式，並將其整合到診療流程中。影像導引標靶技術日趨成熟，能夠更精準地採集較小病灶的樣本，從而減少重複操作的必要性。同時，採樣機制的自動化，例如精密的針頭部署系統和真空輔助抽吸技術，提高了樣本的完整性，降低了操作者差異，從而為後續的分子和基因組分析提供了支持。

此外，平台化思維正顯著興起，相關儀器的開發旨在與數位病理工作流程、電子健康記錄系統和雲端基礎資料儲存庫進行互通。這有助於實現檢體的長期追蹤、診斷元元資料的整合，並支持多學科醫療團隊做出複雜的治療決策。另一個重要趨勢是，出於對便利性、資源最佳化和流程效率的需求，越來越多的診療程序正從住院病房轉移到門診手術中心和診所。

監管機構也正在適應這項技術變革，更加重視臨床效用的證據和上市後監測。因此，製造商正儘早投資於臨床結果研究，以開發數據收集機制，從而證明診斷信心的提高、併發症的減少以及患者吞吐量的增加。這種變革性的轉變提高了臨床檢驗和商業性準備的標準，同時也為創新創造了機會。

對2025年關稅政策發展將如何重塑切片檢查設備相關人員的供應鏈韌性、籌資策略和製造本地化的全面分析

2025年宣布或實施的關稅調整的累積影響將對切片檢查設備領域的採購、供應鏈規劃和競爭定位產生複雜的多方面影響。關稅有可能改變依賴跨境製造和組裝的零件及成品的成本結構，尤其是那些包含來自多個司法管轄區的精密金屬、聚合物和電子子系統的系統。為此，製造商正在重新評估其供應商佈局、物流策略和合約條款，以降低進口關稅增加帶來的風險並保持價格競爭力。

臨床醫生和醫院採購團隊應重點關注總體擁有成本分析，並將關稅可能導致的價格波動納入考慮。雖然一些製造商會暫時承受關稅的影響以維持市場進入，但其他製造商則會重新評估定價或將生產轉移到貿易條件更有利的地區。由於供應商需要重新確認新的製造地或調整物流路線，這些調整可能會造成短期供應緊張和前置作業時間。因此，醫療機構在獲取替換零件和可選醫療設備可能會面臨延誤，這凸顯了庫存計劃和建立可靠服務合約的重要性。

除了營運方面的影響，關稅還可能影響本地化、垂直整合和夥伴關係關係等策略決策。積極評估近岸外包、雙重採購和零件標準化的企業將能夠更好地管理風險並提高成本可預測性。此外，製造商和客戶之間就供應連續性計劃、保固影響和預期服務水準進行透明溝通至關重要。總之，2025 年關稅造成的衝擊不僅會影響價格，還會加速供應鏈和商業策略的結構性變革。

整合的細分洞察揭示了產品類型、臨床應用和醫療保健環境如何相互交織，從而驅動效能需求、購買行為和發展重點。

我們深入的細分分析揭示了臨床需求與設計選擇的交會點，以及最大的機會所在。依產品類型分類，我們提供粗針切片系統、內視鏡解決方案、細針穿刺工具和真空輔助平台。粗針切片系統提供全自動和半自動配置，兼顧操作速度和操作者控制，這些選擇會影響其高效能和對複雜組織標靶的適用性。內視鏡設備根據其軟性或剛性配置進行區分，這決定了其解剖結構的可及性和與現有內視鏡實驗室的兼容性。細針穿刺包括真空驅動和手動技術，優先考慮樣本是否適用於細胞學和分子檢測；而真空輔助平台則涵蓋了從提供更高通量的主機解決方案到優先考慮便攜性和照護現場設備。

在考慮應用時，臨床優先事項因器官系統和手術入路而異。乳房應用包括診斷程序和以篩檢為重點的干涉措施，這要求設備能夠支援高樣本保真度和患者舒適度。腎臟手術可透過開放式或經皮入路進行，每種入路對設備的人體工學和針頭性能都有不同的要求。肝臟取樣主要透過經皮或經經子宮頸路，設備選擇必須考慮血管通路和出血風險。肺部切片切片檢查透過經支氣管或經胸入路進行，分別需要與支氣管鏡引導或經皮成像相容的器械。攝護腺切片檢查採用經會陰和經直腸入路，對感染控制和取樣準確性的日益重視正在影響設備的偏好和臨床方案。從最終用戶的觀點，手術在門診手術中心、診所、診斷實驗室和醫院進行，每種場所都存在一些限制，例如資本投入、人員專業水平、預期吞吐量和消毒基礎設施。

整合這種細分觀點，可以讓相關人員根據臨床工作流程和現場能力，優先考慮產品開發、培訓投資和商業策略。

區域動態和招聘管道決定了美洲、歐洲、中東和非洲以及亞太地區的採購偏好、監管限制和臨床優先事項。

區域動態正在塑造技術採納模式、報銷框架和監管管道，從而在美洲、歐洲、中東和非洲以及亞太地區創造差異化的商業機會。在美洲，成熟的腫瘤治療網路和影像引導介入的廣泛應用支撐了對先進採樣技術的需求，而公立和私立醫療機構的支付環境則促使企業專注於可驗證的價值和營運效率。政策制定者和醫療系統越來越接受能夠縮短住院時間和實現門診病人管理的創新技術，並傾向於選擇適合門診環境的設備。

在歐洲、中東和非洲，為協調監管環境和多元化的醫療保健資金籌措模式所做的努力，造就了一個錯綜複雜的市場格局，其中臨床證據、成本效益和合規性是決定產品應用的關鍵因素。該地區的多個市場強調集中採購和競標採購，這凸顯了長期服務合約和具有競爭力的總成本提案的重要性。同時，在亞太地區，對診斷基礎設施的快速投資、擴大專科醫療服務的覆蓋範圍以及不斷提升的複雜實驗室檢測能力，推動了人們對能夠提供高品質分子分析樣本的設備的需求。本地製造能力和區域供應鏈策略也會影響設備的定價和供應，與當地經銷商和契約製造合作仍然是拓展市場的有效途徑。

每個地區在臨床指南、培訓機會和設施優先事項方面的差異，需要採取獨特的市場策略，以反映當地的監管預期、報銷細微差別和營運實際情況。

策略競爭格局分析，重點在於透過產品演進實現差異化，特別著重於平台整合、臨床檢驗、客戶培訓和永續性。

切片檢查設備產業的競爭格局日益凸顯，技術卓越、強大的臨床檢驗和全面的服務組合是勝利的關鍵。領先企業正投資於可升級和適應多種解剖結構的模組化平台，從而延長產品生命週期，提高醫療服務提供者的投資報酬率。與影像公司、病理實驗室和數位醫療供應商的策略聯盟正在建立連接樣本採集和下游分析的生態系統，從而增強對綜合醫療團隊的價值提案。

透過客戶支援和培訓專案實現差異化競爭的製造商正在贏得市場青睞。此外，對永續性和設備可重複使用性的日益重視，促使企業探索材料科學創新和滅菌通訊協定，以在不損害患者安全的前提下減少對環境的影響。競爭策略還包括地理多元化、針對公共和私人支付方量身定做的定價模式，以及開發資金籌措方案以降低資本受限環境下的進入門檻。

創新發展路徑體現了漸進式改進（例如人體工學和針頭塗層）與顛覆性方法（例如機器人技術、即時影像處理和人工智慧輔助靶向）之間的平衡。能夠證明其在改善手術效果、降低併發症發生率和簡化工作流程方面具有優勢的機構，將更有可能與大型醫療機構和綜合醫療系統建立長期夥伴關係。

為製造商和供應商提供切實可行的策略建議，以加強臨床證據、供應鏈韌性、客戶採納管道和互通性，從而實現永續成長。

產業領導者可以透過優先考慮以下四個策略重點，將洞察轉化為可執行的計劃：臨床證據產生、供應鏈韌性、以客戶為中心的商業化以及互通性。首先，投資於能夠記錄真實世界療效和手術獲益的全面臨床研究，可以增強醫保報銷的論據，並支持持懷疑態度的臨床醫生群體接受該技術。此類工作應包括多中心觀察性研究、用於收集長期療效的註冊登記，以及與病理實驗室合作以證明其下游診斷價值。

其次，透過多元化、近岸外包和完善的供應商資格認證流程來增強供應鏈韌性，可以降低關稅造成的成本轉移和物流中斷風險。製造商應了解關鍵零件的依賴關係，為關鍵零件維持策略性庫存緩衝，並在條件允許的情況下採用雙重採購模式。第三，以客戶為中心的商業化需要量身定做的培訓計劃、靈活的資金籌措模式以及以結果為導向的服務契約，從而協調供應商和醫療服務提供者之間的獎勵。強調易用性、便捷維護和快速獲得技術支持，將加速設備在各種醫療環境中的應用。

最後，優先考慮與影像系統、電子健康記錄和實驗室資訊系統的互通性，能夠為整合醫療團隊創造巨大價值。開放的API、標準化的資料匯出和安全的雲端連接可以促進多學科工作流程，並滿足日益成長的資料驅動型診斷需求。落實這些策略支柱有助於機構降低風險、提升臨床影響力並實現永續成長。

採用透明的混合方法調查方法，整合臨床醫師的第一手見解、技術設備審查、監管文獻和情境分析，以支持可靠的結論。

調查方法結合了定性專家訪談、設備性能評估以及監管和臨床文獻的比較分析，建構了穩健可靠的依證。關鍵資訊來源包括與介入放射科醫生、胸腔外科醫生、乳房外科醫生、病理學家和採購專業人員進行結構化討論，以了解實際操作中的偏好、痛點和推廣促進因素。此外，也透過對設備架構、製造流程和服務模式的技術評估，將這些觀點與臨床需求、工程實際情況結合。

二次研究整合了同行評審的臨床研究、監管文件、專業協會指南和供應商技術文檔，以檢驗有關樣本品質、併發症發生率和設備易用性的說法。調查方法強調對關鍵見解和已發表的證據進行交叉檢驗，以減少偏差並確保結論既反映實踐也反映已記錄的結果。情境分析用於評估供應鏈對關稅變化的反應，以及不同的採購模式如何影響不同醫療機構環境下的設備採用。

我們始終注重透明的採購、可複製的分析步驟以及納入不同相關人員的聲音，從而獲得了可操作的見解，這些見解將引起臨床醫生、採購領導者和企業負責人的共鳴。

簡明扼要的結論整合了技術進步、臨床檢驗的必要性以及供應鏈的考量，從而確定了切片檢查設備相關人員的策略重點。

總而言之，切片檢查設備正處於曲折點，技術進步、臨床工作流程的轉變以及外部經濟壓力既帶來了風險，也帶來了機會。雖然諸如提高準確性、自動化程度和平台互通性等技術創新增強了診斷管道，但醫療服務提供者的期望和支付方的審查促使人們需要明確的臨床和營運價值證據。關稅政策的變化和供應鏈的應對措施正在加速向本地化和增強韌性的策略轉變，因此，相關人員必須主動評估風險並調整採購和生產策略。

將產品開發與臨床醫生需求相結合、投資於嚴謹的療效研究並建立適應性強的供應鏈的機構，將最有利於從這個不斷變化的市場格局中獲益。與包括影像合作夥伴、病理服務機構和醫療系統在內的整個生態系統開展合作，將進一步擴大影響力，並支持更個人化和高效的診斷管道。最終，循證創新和務實的風險緩解策略執行將決定哪些公司能夠引領這個充滿活力的行業。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 引入機器人切片檢查平台，以提高準確性並縮短手術時間
  • 液態生物檢體技術的發展使得對患者血液樣本中的癌症生物標記進行非侵入性檢測成為可能。
  • 開發用於細胞層面即時組織學評估的高解析度光學活體組織切片探針
  • 將人工智慧演算法整合到切片檢查成像系統中，實現病灶的自動檢測。
  • 改用一次性切片穿刺針，以最大限度地減少交叉感染並簡化工作流程。
  • 擴展遠端病理學能力，以支援遠端切片檢查手術諮詢和診斷
  • 微波和射頻消融術的出現，以及與切片檢查設備相結合，實現了同時取樣和治療。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按產品類型切片檢查設備市場

  • 粗針切片
    • 自動的
    • 半自動
  • 內視鏡檢查
    • 柔軟的
    • 難的
  • 細針穿刺法
    • 吸
    • 手動的
  • 真空輔助
    • 基於主機
    • 手持式

第9章切片檢查設備市場：依應用領域分類

  • 胸部
    • 診斷
    • 篩檢
  • 腎
    • 剖腹手術
    • 經皮
  • 肝
    • 經皮
    • 經頸靜脈
  • 肺
    • 經支氣管
    • 經胸
  • 攝護腺
    • 經會陰
    • 經直腸

第10章 按最終用戶分類的切片檢查設備市場

  • 門診手術中心
  • 診所
  • 診斷實驗室
  • 醫院

第11章 各地區切片檢查設備市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 按組別分類的切片檢查設備市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國切片檢查設備市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Hologic, Inc.
    • Becton, Dickinson and Company
    • Boston Scientific Corporation
    • Olympus Corporation
    • Cook Incorporated
    • Argon Medical Devices, Inc.
    • Merit Medical Systems, Inc.
    • Teleflex Incorporated
    • Medtronic plc
    • Ethicon Inc.
Product Code: MRR-4103B31E073F

The Biopsy Devices Market is projected to grow by USD 24.45 billion at a CAGR of 11.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.46 billion
Estimated Year [2025] USD 11.61 billion
Forecast Year [2032] USD 24.45 billion
CAGR (%) 11.19%

Concise foundational overview of biopsy device landscape capturing clinical drivers, technological advances, regulatory influences, and procurement priorities for leaders

Biopsy devices are central to diagnostic pathways across oncology, nephrology, hepatology, and pulmonary medicine, and their evolution directly shapes clinical workflows, device adoption, and procurement priorities. Contemporary drivers include a convergence of technological innovation, procedural standardization, and an increasing focus on minimally invasive techniques that prioritize patient comfort and diagnostic yield. In parallel, regulatory scrutiny and payer policies are influencing device design, clinical evidence generation, and value demonstration, which together determine adoption speed across care settings.

Clinicians are demanding devices that reduce procedure time while enhancing sample quality, particularly as molecular diagnostics and next-generation sequencing become routine components of clinical decision-making. As a result, manufacturers are directing development toward precision-guided systems, automation of sampling mechanisms, and platforms that integrate with digital pathology and data management tools. At the same time, providers are balancing capital investment with throughput needs, which elevates the importance of lifecycle costs, training requirements, and interoperability with existing imaging and endoscopy suites.

Moving forward, stakeholders must reconcile clinical imperatives with economic realities. Procurement teams and clinical leaders are increasingly looking for evidence of real-world effectiveness and operational benefits beyond controlled trials. Therefore, device developers and strategy teams should prioritize robust clinical validation, user-centered design, and clear value narratives that resonate with both proceduralists and hospital administrators. Taken together, these elements create a complex but actionable landscape for innovation and adoption in biopsy technologies.

Detailed synthesis of technological convergence, automation, and clinical workflow evolution that is reshaping biopsy device utilization and validation across care settings

The biopsy device landscape is undergoing transformative shifts driven by converging advances in imaging, automation, and data-driven diagnostics, and these trends are reshaping how biopsies are performed and integrated into care pathways. Image-guided targeting has matured, enabling more accurate sampling of smaller lesions and reducing the need for repeat procedures. Concurrently, automation in sampling mechanics, such as refined needle deployment systems and vacuum-assisted extraction, is improving sample integrity and reducing operator variability, which in turn supports downstream molecular and genomic analyses.

Additionally, there is a noticeable shift toward platform thinking, where devices are developed to interoperate with digital pathology workflows, electronic health record systems, and cloud-based data repositories. This facilitates longitudinal tracking of samples, integration of diagnostic metadata, and support for multidisciplinary care teams making complex treatment decisions. Another important dynamic is the movement of procedures from inpatient wards to ambulatory surgical centers and clinic-based settings, driven by demand for convenience, resource optimization, and procedural efficiency.

Regulatory pathways are adapting to these technological shifts, emphasizing evidence of clinical utility and post-market surveillance. As a result, manufacturers are investing earlier in clinical outcomes studies and in building data capture mechanisms that demonstrate improved diagnostic confidence, reduced complications, and enhanced patient throughput. Taken together, these transformative shifts create opportunities for innovation while raising the bar for clinical validation and commercial readiness.

Comprehensive analysis of how 2025 tariff developments are reshaping supply chain resilience, procurement strategies, and manufacturing localization for biopsy device stakeholders

The cumulative impact of tariff policy changes announced or implemented in 2025 introduces a layer of complexity for procurement, supply chain planning, and competitive positioning in the biopsy device arena. Tariffs can alter cost structures for components and finished devices that rely on cross-border manufacturing and assembly, particularly for systems incorporating precision metals, polymers, and electronic subsystems sourced from multiple jurisdictions. In response, manufacturers are reassessing supplier footprints, logistics strategies, and contractual terms to mitigate exposure to incremental import duties and to preserve pricing competitiveness.

Clinicians and hospital procurement teams should expect an emphasis on total cost of ownership analyses that account for potential tariff-driven price volatility. Some manufacturers may absorb tariff impacts temporarily to maintain market access, whereas others will recalibrate pricing or shift production to locations with more favorable trade terms. These adjustments can create short-term supply constraints or lead times as suppliers requalify new manufacturing sites or reroute logistics. In turn, providers may face delays in obtaining replacement parts or elective devices, which underscores the importance of inventory planning and of establishing reliable service agreements.

Beyond operational effects, tariffs can influence strategic decisions around localization, vertical integration, and partnerships. Organizations that proactively evaluate nearshoring, dual sourcing, or component standardization will better manage risk and cost predictability. Furthermore, transparent communication between manufacturers and customers about supply continuity plans, warranty implications, and service-level expectations becomes critical. In sum, tariff-induced perturbations in 2025 will not only affect pricing but also accelerate structural shifts across supply chains and commercial strategies.

Integrated segmentation insights revealing how product types, clinical applications, and care settings converge to define performance needs, purchasing behavior, and development priorities

Insightful segmentation analysis clarifies where clinical needs intersect with design choices and where commercial opportunities are most concentrated. By product type, the landscape spans core needle systems, endoscopic solutions, fine needle aspiration tools, and vacuum-assisted platforms. Core needle systems include both automatic and semi-automatic variants that balance deployment speed with operator control, and these choices influence suitability across high-throughput and complex tissue targets. Endoscopic devices are differentiated by flexible and rigid configurations, which determine accessibility to anatomical sites and compatibility with existing endoscopy suites. Fine needle aspiration encompasses aspiration-driven and manual techniques that prioritize sample adequacy for cytology and molecular assays, while vacuum-assisted platforms range from console-based solutions offering higher throughput to handheld devices that favor portability and point-of-care use.

When considering application, clinical priorities vary by organ system and by the procedural approach used. Breast applications include diagnostic procedures and screening-focused interventions, requiring devices that support high sample fidelity and patient comfort. Kidney procedures are performed via open or percutaneous approaches, each imposing distinct device ergonomics and needle performance needs. Liver sampling is primarily percutaneous or transjugular, and device selection must account for vascular access considerations and bleeding risk. Lung biopsies executed via transbronchial or transthoracic routes demand tools compatible with bronchoscopic guidance or percutaneous imaging, respectively. Prostate procedures employ transperineal and transrectal approaches, and the growing emphasis on infection control and sampling accuracy is affecting device preference and clinical protocols. From an end-user perspective, procedures occur across ambulatory surgical centers, clinics, diagnostic laboratories, and hospitals, and each setting imposes constraints around capital expenditure, staffing expertise, throughput expectations, and sterilization infrastructure.

Integrating these segmentation perspectives enables stakeholders to prioritize product development, training investments, and commercial strategies that are aligned with clinical workflows and institutional capabilities.

Regional dynamics and adoption pathways that define procurement preferences, regulatory constraints, and clinical priorities across the Americas, Europe Middle East & Africa, and Asia-Pacific geographies

Regional dynamics shape adoption patterns, reimbursement frameworks, and regulatory pathways, creating differentiated opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, mature oncology care networks and widespread adoption of image-guided interventions support demand for advanced sampling technologies, while private and public payer environments drive a focus on demonstrable value and operational efficiency. Policymakers and health systems are increasingly receptive to innovations that reduce hospital stays and enable outpatient management, which favors devices compatible with ambulatory settings.

In Europe, Middle East & Africa, regulatory harmonization efforts and diverse healthcare financing models create a nuanced landscape where clinical evidence, cost-effectiveness, and compliance are key determinants of uptake. Several markets in this region emphasize centralized procurement and tender-based purchasing, which elevates the importance of long-term service agreements and competitive total cost propositions. Meanwhile, in the Asia-Pacific region, rapid investments in diagnostic infrastructure, expanding access to specialist care, and growing capacity for complex laboratory testing are stimulating interest in devices that deliver high-quality samples for molecular analysis. Local manufacturing capabilities and regional supply chain strategies also influence device pricing and availability, and partnerships with local distributors or contract manufacturers remain a pragmatic route to market expansion.

Across all regions, differences in clinical guidelines, training availability, and institutional priorities require tailored market approaches that reflect local regulatory expectations, reimbursement nuances, and operational realities.

Strategic competitor landscape analysis highlighting differentiation through platform integration, clinical validation, customer training, and sustainability-driven product evolution

Competitive positioning within the biopsy device landscape is increasingly determined by the ability to pair engineering excellence with robust clinical validation and comprehensive service offerings. Leading firms are investing in modular platforms that can be upgraded or adapted for multiple anatomical targets, which extends product lifecycles and enhances return on investment for providers. Strategic collaborations with imaging companies, pathology labs, and digital health vendors are creating ecosystems that link sample acquisition to downstream analytics, thereby strengthening value propositions for integrated care teams.

Manufacturers differentiating through customer support and training programs are gaining market preference, since procedural success and device utilization are tightly linked to operator proficiency. Additionally, a growing emphasis on sustainability and device reusability is prompting companies to explore materials science innovations and sterilization protocols that reduce environmental impact without compromising patient safety. Competitive strategies also include geographic diversification, selective pricing models tailored to public and private payers, and the development of financing arrangements that lower barriers to adoption in capital-constrained settings.

Innovation pipelines reflect a balance between incremental improvements-such as ergonomics and needle coatings-and disruptive approaches that combine robotics, real-time imaging, and AI-assisted targeting. Organizations that can demonstrate improved procedural outcomes, reduced complication rates, and streamlined workflows are well positioned to secure long-term partnerships with high-volume providers and integrated health systems.

Actionable strategic recommendations for manufacturers and providers to fortify clinical evidence, supply chain resilience, customer adoption pathways, and interoperability for sustained growth

Industry leaders can translate insights into actionable plans by prioritizing four strategic thrusts: clinical evidence generation, supply chain resilience, customer-centric commercialization, and interoperability. First, investing in comprehensive clinical studies that document real-world effectiveness and procedural advantages will strengthen reimbursement discussions and support adoption among skeptical clinician groups. These efforts should include multicenter observational studies, registries that capture longitudinal outcomes, and collaborations with pathology labs to demonstrate downstream diagnostic value.

Second, strengthening supply chain resilience through diversification, nearshoring, and robust supplier qualification processes will reduce exposure to tariff-driven cost shifts and logistical disruptions. Manufacturers should map critical component dependencies, maintain strategic inventory buffers for key parts, and pursue dual sourcing where feasible. Third, customer-centric commercialization requires tailored training programs, flexible financing models, and outcome-focused service agreements that align incentives between vendors and providers. Emphasizing ease of use, maintenance simplicity, and rapid access to technical support will accelerate device adoption across diverse care settings.

Finally, prioritizing interoperability with imaging systems, electronic health records, and laboratory information systems will create compelling value for integrated care teams. Open APIs, standardized data exports, and secure cloud connectivity can facilitate multidisciplinary workflows and support the growing demand for data-driven diagnostics. By executing on these strategic pillars, organizations can reduce risk, enhance clinical impact, and achieve sustainable growth.

Transparent mixed-methods research methodology integrating primary clinician insights, technical device reviews, regulatory literature, and scenario analysis to support robust conclusions

The research approach combines qualitative expert interviews, device performance reviews, and comparative analysis of regulatory and clinical literature to create a robust and defensible evidence base. Primary inputs included structured discussions with interventional radiologists, thoracic and breast surgeons, pathologists, and procurement professionals to capture real-world procedural preferences, pain points, and adoption drivers. These perspectives were contextualized with technical assessments of device architectures, manufacturing considerations, and service models to align clinical needs with engineering realities.

Secondary research synthesized peer-reviewed clinical studies, regulatory filings, guidelines from professional societies, and supplier technical documents to validate claims related to sample quality, complication rates, and device usability. The methodology emphasized cross-validation between primary insights and published evidence to reduce bias and to ensure that conclusions reflect both practice and documented outcomes. Scenario analysis was used to evaluate supply chain responses to tariff changes and to assess how varying procurement models influence adoption in different institutional settings.

Throughout, the emphasis was on transparent sourcing, reproducible analytic steps, and the inclusion of diverse stakeholder voices to produce actionable findings that resonate with clinicians, procurement leaders, and corporate strategists.

Concise conclusion synthesizing technological progress, clinical validation imperatives, and supply chain considerations that define strategic priorities for biopsy device stakeholders

In sum, biopsy devices are at an inflection point where technological advancements, changing clinical workflows, and external economic pressures converge to create both risk and opportunity. Innovations in targeting accuracy, automation, and platform interoperability are enhancing diagnostic pathways, while provider expectations and payer scrutiny are elevating the need for clear evidence of clinical and operational value. Tariff developments and supply chain responses are accelerating strategic shifts toward localization and resilience, making it imperative for stakeholders to proactively assess risks and adjust procurement and manufacturing strategies.

Organizations that align product development with clinician needs, invest in rigorous outcomes research, and build adaptable supply chains will be best positioned to capture the benefits of this evolving landscape. Collaboration across the ecosystem-including imaging partners, pathology services, and health systems-will further amplify impact and support more personalized and efficient diagnostic pathways. Ultimately, pragmatic execution of evidence-driven innovation and risk mitigation strategies will determine who leads in this dynamic sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of robotic-assisted biopsy platforms to enhance precision and reduce procedure time
  • 5.2. Growth of liquid biopsy technologies enabling non-invasive detection of cancer biomarkers in patient blood samples
  • 5.3. Development of high-definition optical biopsy probes for real-time histological assessment at the cellular level
  • 5.4. Integration of artificial intelligence algorithms in biopsy imaging systems for automated lesion detection
  • 5.5. Shift toward single-use disposable biopsy needles to minimize cross-contamination and streamline workflow
  • 5.6. Expansion of telepathology capabilities to support remote biopsy procedure consultations and diagnostics
  • 5.7. Emergence of microwave and radiofrequency ablation integrated with biopsy devices for simultaneous sampling and therapy

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biopsy Devices Market, by Product Type

  • 8.1. Core Needle
    • 8.1.1. Automatic
    • 8.1.2. Semi Automatic
  • 8.2. Endoscopic
    • 8.2.1. Flexible
    • 8.2.2. Rigid
  • 8.3. Fine Needle Aspiration
    • 8.3.1. Aspiration
    • 8.3.2. Manual
  • 8.4. Vacuum Assisted
    • 8.4.1. Console Based
    • 8.4.2. Handheld

9. Biopsy Devices Market, by Application

  • 9.1. Breast
    • 9.1.1. Diagnostic
    • 9.1.2. Screening
  • 9.2. Kidney
    • 9.2.1. Open
    • 9.2.2. Percutaneous
  • 9.3. Liver
    • 9.3.1. Percutaneous
    • 9.3.2. Transjugular
  • 9.4. Lung
    • 9.4.1. Transbronchial
    • 9.4.2. Transthoracic
  • 9.5. Prostate
    • 9.5.1. Transperineal
    • 9.5.2. Transrectal

10. Biopsy Devices Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Clinics
  • 10.3. Diagnostic Laboratories
  • 10.4. Hospitals

11. Biopsy Devices Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Biopsy Devices Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Biopsy Devices Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Hologic, Inc.
    • 14.3.2. Becton, Dickinson and Company
    • 14.3.3. Boston Scientific Corporation
    • 14.3.4. Olympus Corporation
    • 14.3.5. Cook Incorporated
    • 14.3.6. Argon Medical Devices, Inc.
    • 14.3.7. Merit Medical Systems, Inc.
    • 14.3.8. Teleflex Incorporated
    • 14.3.9. Medtronic plc
    • 14.3.10. Ethicon Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOPSY DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOPSY DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BIOPSY DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOPSY DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL BIOPSY DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BIOPSY DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. BIOPSY DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BIOPSY DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOPSY DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOPSY DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AUTOMATIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AUTOMATIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AUTOMATIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AUTOMATIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AUTOMATIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AUTOMATIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SEMI AUTOMATIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SEMI AUTOMATIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SEMI AUTOMATIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SEMI AUTOMATIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SEMI AUTOMATIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SEMI AUTOMATIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FLEXIBLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FLEXIBLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FLEXIBLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FLEXIBLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FLEXIBLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FLEXIBLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOPSY DEVICES MARKET SIZE, BY RIGID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOPSY DEVICES MARKET SIZE, BY RIGID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOPSY DEVICES MARKET SIZE, BY RIGID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOPSY DEVICES MARKET SIZE, BY RIGID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOPSY DEVICES MARKET SIZE, BY RIGID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOPSY DEVICES MARKET SIZE, BY RIGID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ASPIRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ASPIRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ASPIRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ASPIRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ASPIRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOPSY DEVICES MARKET SIZE, BY ASPIRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOPSY DEVICES MARKET SIZE, BY MANUAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CONSOLE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CONSOLE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CONSOLE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CONSOLE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CONSOLE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CONSOLE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HANDHELD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HANDHELD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HANDHELD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HANDHELD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HANDHELD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HANDHELD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOPSY DEVICES MARKET SIZE, BY BREAST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOPSY DEVICES MARKET SIZE, BY SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOPSY DEVICES MARKET SIZE, BY KIDNEY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BIOPSY DEVICES MARKET SIZE, BY OPEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOPSY DEVICES MARKET SIZE, BY OPEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BIOPSY DEVICES MARKET SIZE, BY OPEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOPSY DEVICES MARKET SIZE, BY OPEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BIOPSY DEVICES MARKET SIZE, BY OPEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOPSY DEVICES MARKET SIZE, BY OPEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LIVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PERCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSJUGULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSJUGULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSJUGULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSJUGULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSJUGULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSJUGULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BIOPSY DEVICES MARKET SIZE, BY LUNG, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSBRONCHIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSBRONCHIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSBRONCHIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSBRONCHIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSBRONCHIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSBRONCHIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSTHORACIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSTHORACIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSTHORACIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSTHORACIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSTHORACIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSTHORACIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BIOPSY DEVICES MARKET SIZE, BY PROSTATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSPERINEAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSPERINEAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSPERINEAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSPERINEAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSPERINEAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSPERINEAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSRECTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSRECTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSRECTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSRECTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSRECTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BIOPSY DEVICES MARKET SIZE, BY TRANSRECTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BIOPSY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BIOPSY DEVICES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BIOPSY DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BIOPSY DEVICES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BIOPSY DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BIOPSY DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BIOPSY DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS BIOPSY DEVICES MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS BIOPSY DEVICES MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS BIOPSY DEVICES MARKET SIZE, BY LUNG, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS BIOPSY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2025-2032 (USD MILLION)
  • TABLE 291. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 292. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 293. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 294. LATIN AMERICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY LUNG, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE, MIDDLE EAST & AFRICA BIOPSY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE BIOPSY DEVICES MARKET SIZE, BY CORE NEEDLE, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE BIOPSY DEVICES MARKET SIZE, BY ENDOSCOPIC, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPE BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPE BIOPSY DEVICES MARKET SIZE, BY FINE NEEDLE ASPIRATION, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPE BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPE BIOPSY DEVICES MARKET SIZE, BY VACUUM ASSISTED, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPE BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPE BIOPSY DEVICES MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPE BIOPSY DEVICES MARKET SIZE, BY BREAST, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPE BIOPSY DEVICES MARKET SIZE, BY BREAST, 2025-2032 (USD MILLION)
  • TABLE 337. EUROPE BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2018-2024 (USD MILLION)
  • TABLE 338. EUROPE BIOPSY DEVICES MARKET SIZE, BY KIDNEY, 2025-2032 (USD MILLION)
  • TABLE 339. EUROPE BIOPSY DEVICES MARKET SIZE, BY LIVER, 2018-2024 (USD MILLION)
  • TABLE 340. EUROPE BIOPSY DEVICES MARKET SIZE, BY LIVER, 2025-2032 (USD MILLION)
  • TABLE 341. EUROPE BIOPSY DEVICES MARKET SIZE, BY LUNG, 2018-2024 (USD MILLION)
  • TABLE 342. EUROPE BIOPSY DEVICES MARKET SIZE, BY LUNG, 2025-2032 (USD MILLION)
  • TABLE 343. EUROPE BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2018-2024 (USD MILLION)
  • TABLE 344. EUROPE BIOPSY DEVICES MARKET SIZE, BY PROSTATE, 2025-2032 (USD MILLION)
  • TABLE 345. EUROPE BIOPSY DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 346. EUROPE BIOPSY DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 347. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 348. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 349. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 350. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 351. MIDDLE EAST BIOPSY DEVICES MARKET SIZE, BY C